Investment Thesis
BridgeBio is technically insolvent with negative stockholders' equity of -$2.3B and is burning -$197.3M in annual operating cash flow, requiring significant capital raises or near-term profitability achievement. Despite 126% YoY revenue growth, net losses deteriorated 35.3% YoY with an -84.3% net margin, indicating operational losses are accelerating faster than revenue. The company faces imminent balance sheet restructuring risk with $2.7B debt against $880M cash and unprofitable operations.
Strengths
- Strong revenue growth of 126.3% YoY demonstrates robust commercial demand
- Adequate short-term liquidity with 1.52x current ratio and 1.48x quick ratio
- $879.9M cash position provides 4-5 year operational runway at current burn rates
Risks
- Critical: Negative stockholders' equity of -$2.3B indicates technical balance sheet insolvency
- Severe cash burn of -$197.3M operating CF with deteriorating profitability trend (net income -35.3% YoY despite revenue growth)
- Long-term debt of $2.7B with negative interest coverage ratio of -5.0x; cannot service debt from operations
- Negative net margin of -84.3% and operating margin of -54.5% indicate structural unprofitability
- Will require equity dilution through capital raises or debt restructuring within medium term
Key Metrics to Watch
- Quarterly operating cash flow trend and cash runway depletion rate
- Quarterly gross margin trends as products scale commercially
- Path to operating profitability timeline and milestones
- Debt refinancing needs and equity issuance announcements
Financial Metrics
Revenue
194.5M
Net Income
-164.0M
EPS (Diluted)
$-0.84
Free Cash Flow
-197.3M
Total Assets
1.4B
Cash
879.9M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-54.5%
Net Margin
-84.3%
ROE
N/A
ROA
-12.0%
FCF Margin
-101.5%
Balance Sheet & Liquidity
Current Ratio
1.52x
Quick Ratio
1.48x
Debt/Equity
N/A
Debt/Assets
265.5%
Interest Coverage
-5.00x
Long-term Debt
2.7B
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-08T08:04:41.577741 |
Data as of: 2026-03-31 |
Powered by Claude AI